Finerenone attenuates downregulation of the kidney GLP-1 receptor and glucagon receptor and cardiac GIP receptor in mice with comorbid diabetes
Through its anti-fibrotic actions, finerenone reverses Glp1r and Gcgr downregulation in the diabetic kidney. Both finerenone and GLP-1R agonists have proven cardiorenal benefits, whereas receptor co-agonists are approved or under development. The current findings provide preclinical rationale for the combined use of finerenone with the GLP-1R agonist family. They also provide mechanism of action insights into the potential benefit of finerenone in people with diabetes for whom GLP-1R agonists or co-agonists may not be indicated.
Authors
- Sri Nagarjun Batchu
- Duc Tin Tran (ORCID: https://orcid.org/0000-0003-0097-4465)
- Madiha Zahra Syeda (ORCID: https://orcid.org/0009-0006-6035-3854)
- Andrew Advani (ORCID: https://orcid.org/0000-0003-0497-645X)
- Suzanne L. Advani
- Youan Liu
- Harmandeep Kaur
- Emily S. H. Yeung
- Lisa Y. Q. Hong
Institutions
- St. Michael's Hospital (CA)
Publication Details
- Journal
- Diabetology & Metabolic Syndrome
- Published
- 2024-11-24
- DOI
- https://doi.org/10.1186/s13098-024-01525-3
- Citations
- 7
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.50
Funders
- Heart and Stroke Foundation of Canada
- St. Michael's Hospital Foundation
- Kidney Foundation of Canada
- Canada Foundation for Innovation
- Canadian Institutes of Health Research
- Banting and Best Diabetes Centre, University of Toronto